10 reports of this reaction
3.1% of all BENZETHONIUM CHLORIDE reports
#5 most reported adverse reaction
CONTRAINDICATED PRODUCT ADMINISTERED is the #5 most commonly reported adverse reaction for BENZETHONIUM CHLORIDE, manufactured by McKesson. There are 10 FDA adverse event reports linking BENZETHONIUM CHLORIDE to CONTRAINDICATED PRODUCT ADMINISTERED. This represents approximately 3.1% of all 326 adverse event reports for this drug.
Patients taking BENZETHONIUM CHLORIDE who experience contraindicated product administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONTRAINDICATED PRODUCT ADMINISTERED is moderately reported among BENZETHONIUM CHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to contraindicated product administered, the following adverse reactions have been reported for BENZETHONIUM CHLORIDE:
The following drugs have also been linked to contraindicated product administered in FDA adverse event reports:
CONTRAINDICATED PRODUCT ADMINISTERED has been reported as an adverse event in 10 FDA reports for BENZETHONIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONTRAINDICATED PRODUCT ADMINISTERED accounts for approximately 3.1% of all adverse event reports for BENZETHONIUM CHLORIDE, making it a notable side effect.
If you experience contraindicated product administered while taking BENZETHONIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.